Introduction: Opioid analgesics are widely used as effective analgesics for the treat-
ever, the analgesic efficacy of opioids is well known to vary widely among individuals, thus complicating their effective and safe clinical use. 3, 4 Therefore, although the same amount of opioid analgesics may be administered to different patients, it may occasionally cause insufficient analgesia or side effects among some individuals, such as nausea, vomiting, constipation, and respiratory depression. 5 For example, the minimal effective analgesic concentrations (MEACs) of morphine and fentanyl that are required for adequate analgesia vary from 6.3 to 53.6 ng/mL and 0.2 to 2.0 ng/mL, respectively. [6] [7] [8] [9] This suggests that the MEAC is five-to tenfold different among individuals. Thus, effective pain treatment is often hampered by significant differences in opioid sensitivity. Empirical methods of administration that are currently performed by trial and error are an imperfect practice that can result in delayed analgesia and possibly overdose ( Figure 1 ). ethnic origin, hepatic or renal function, type of surgery, surgical methods, duration of surgery, anxiety, and psychological distress. [10] [11] [12] [13] In this section, we describe each of these factors.
| Environmental factors
Various environmental factors have been reported. Among these, advancing age has been shown to reduce morphine requirements because age has been suggested to blunt peripheral nociceptive function. 11 Additionally, fentanyl use for pain management is more in females than in males. 14 
| Psychological factors
Many studies have reported associations between depression and pain. The prevalence of pain in depressed cohorts and the prevalence of depression in pain cohorts are higher than the prevalence when these conditions are examined individually. 15 Indeed, the prevalence of pain in depressed patients was approximately 60%, and the intensity of depression was generally higher in patients with greater pain. 16 However, the number of United States Food and Drug Administration (FDA)-approved drug label modifications that contain pharmacogenetic information has significantly increased. 25 Additionally, the Clinical Pharmacogenetics Implementation Consortium published guidelines for codeine, clopidogrel, and tacrolimus dosing based on pharmacogenetics testing. [26] [27] [28] An IVD companion diagnostic device provides information that is essential for the safe and effective use of a corresponding therapeutic product. The FDA issued draft guidance for IVD companion diagnostic devices in July, 2011.
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F I G U R E 1 Illustration of individual differences in opioid requirements. Although the blood opioid concentration changes similarly after administration (arrows) and the difference between the minimal effective analgesic concentration (MEAC) (solid line) and maximum concentration with pain (MCP) (dashed line) is low among individuals, the clinical response can differ between patients because of five-to tenfold interpatient differences in the MEAC. Therefore, a particular opioid dose that produces satisfactory pain relief in some patients may be either too low (resulting in insufficient analgesia) or too high (resulting in adverse effects) in other patients YOSHIDA ET AL. Figure 2 ). Many studies have reported associations between gene polymorphisms in these molecules, some of which are described below, and pain/opioid sensitivity (Table 1) . 
| CREB1
The inhibition of adenylyl cyclase inhibits the production of cyclic adenosine monophosphate (cAMP), thus decreasing the active form of protein kinase A, phosphorylating cAMP-responsive element-binding protein (CREB), decreasing various gene expression in the nucleus, and subsequently affecting analgesia. 41 Indeed, the administration of cAMP intracerebrally or intravenously antagonized morphine analgesia, and all of the major behavioral effects of morphine, including analgesia, were attenuated in mice that lacked adenylyl cyclase 5. 42, 43 A recent study found that higher CREB1 mRNA expression levels in subjects with the C/C genotype in the rs2952768 SNP may result in elevated CREB function and decreased sensitivity to the rewarding effects of opioids, resulting in greater postoperative opioid analgesic requirements. 44 
| GIRK2
GIRK channels are expressed in many tissues and activated by several G i/o protein-coupled receptors, such as opioid receptors, and thus are known to be involved in the modulation of opioidinduced analgesia. 45 Several studies that used knockout mice showed that opioid-induced GIRK channel activation, co-expressed with opioid receptors, inhibited nociceptive transmission and thus opioid-induced analgesia. 46, 47 Recently, an association was found between opioid analgesic sensitivity and the rs2835859 SNP in the GIRK2 (KCNJ6) gene, in which carriers of the C allele of this SNP required less analgesics compared with noncarriers after painful cosmetic surgery. 48 VACCs have been especially thought to play critical roles in pain pathways. In Japanese patients who underwent sagittal split ramus osteotomy, the analgesic effects of fentanyl were related to genotype of the CACNA1E gene. Subjects with the minor G allele of the rs3845446 A/G SNP required less fentanyl for adequate postoperative pain control after painful cosmetic surgery, 14 although those with the same allele reportedly required greater fentanyl after laparoscopic colectomy. 52 
| CACNA1E

| PERSONALIZED PAIN TREATMENT
Although various factors that are related to individual differences in opioid sensitivity have been identified, a prediction model that calculates appropriate opioid analgesic requirements has not yet been established. Therefore, we sought to construct prediction formulas for individual opioid analgesic requirements based on genetic polymorphisms and clinical data using patients in pain management with opioid drugs. 53 Constructing prediction formulas based on data from patients with cancer pain is difficult because the mechanism, severity, and nature of cancer pain can differ substantially between patients. 54 Thus, we investigated patients who underwent mandibular sagittal split ramus osteotomy, which is highly standardized at our institute with regard to surgical procedures, the duration of surgery, and the skill of the surgeons. Because these patients are usually young and healthy and expected to experience similar levels of pain after surgery, they may be ideal for evaluating the analgesic effects of opioids. 39 Stepwise multiple linear regression analysis was performed to construct prediction formulas and predict postoperative fentanyl requirements based on parameters that may affect the anal- interval: 5.9-19.6, P = 3.64 9 10 À15 ), implying that this allele has 60.7% sensitivity and 87.5% specificity when we apply HLA-A * 3101 as a risk predictor for carbamazepine-induced cADRs. 56 In the future, we expect that more effective personalized pain treatment may be achieved by taking side effects into account.
| CONCLUSION
The studies that were presented in this review have shown that individual differences in opioid analgesic requirements are very large, and various factors (eg, genetic factors) are involved in such differences. Although more research is needed, better pain treatment may be provided to patients who suffer from postoperative pain using prediction formulas based on pharmacogenetics research.
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F I G U R E 3 Construction and verification of prediction formula for individual opioid analgesics requirements. We constructed a prediction formula for individual opioid analgesic requirements during the first 24-h postoperative period using patients who underwent mandibular sagittal split ramus osteotomy and validated the utility of the formula in another type of surgery, major abdominal surgery 
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